 Charles Neff
Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 19 | 2022 | 2453 | 1.690 |
Why?
| | HIV-1 | 11 | 2018 | 768 | 1.460 |
Why?
| | Aptamers, Nucleotide | 4 | 2023 | 73 | 1.340 |
Why?
| | Anti-Inflammatory Agents | 4 | 2022 | 445 | 1.130 |
Why?
| | CD4-Positive T-Lymphocytes | 10 | 2021 | 959 | 0.980 |
Why?
| | Herpesvirus 1, Human | 1 | 2023 | 76 | 0.830 |
Why?
| | Cyclohexanes | 2 | 2011 | 22 | 0.740 |
Why?
| | Macrophages, Alveolar | 2 | 2020 | 348 | 0.700 |
Why?
| | Triazoles | 2 | 2011 | 125 | 0.670 |
Why?
| | Microbiota | 5 | 2022 | 648 | 0.670 |
Why?
| | Interleukin-10 | 2 | 2022 | 293 | 0.640 |
Why?
| | Vagina | 4 | 2012 | 146 | 0.590 |
Why?
| | Feces | 3 | 2021 | 372 | 0.580 |
Why?
| | CD8-Positive T-Lymphocytes | 4 | 2021 | 686 | 0.570 |
Why?
| | Polysaccharides, Bacterial | 2 | 2022 | 66 | 0.570 |
Why?
| | Viral Load | 4 | 2018 | 405 | 0.560 |
Why?
| | RNA, Small Interfering | 4 | 2012 | 534 | 0.550 |
Why?
| | Inflammation | 5 | 2022 | 2464 | 0.520 |
Why?
| | Homosexuality, Male | 4 | 2022 | 169 | 0.490 |
Why?
| | T-Lymphocytes, Regulatory | 2 | 2021 | 337 | 0.480 |
Why?
| | Bacteria | 3 | 2022 | 725 | 0.480 |
Why?
| | Immune Tolerance | 1 | 2016 | 321 | 0.460 |
Why?
| | Gastrointestinal Microbiome | 4 | 2021 | 502 | 0.410 |
Why?
| | B7-H1 Antigen | 4 | 2019 | 137 | 0.400 |
Why?
| | Anti-HIV Agents | 4 | 2016 | 663 | 0.400 |
Why?
| | CCR5 Receptor Antagonists | 1 | 2011 | 6 | 0.380 |
Why?
| | Programmed Cell Death 1 Receptor | 5 | 2019 | 193 | 0.380 |
Why?
| | Leukocytes, Mononuclear | 5 | 2022 | 489 | 0.370 |
Why?
| | Post-Exposure Prophylaxis | 1 | 2010 | 6 | 0.370 |
Why?
| | T-Lymphocytes, Helper-Inducer | 2 | 2011 | 127 | 0.370 |
Why?
| | Anti-Infective Agents, Local | 1 | 2011 | 39 | 0.370 |
Why?
| | Pyrrolidinones | 1 | 2010 | 25 | 0.360 |
Why?
| | Sexual and Gender Minorities | 3 | 2022 | 138 | 0.350 |
Why?
| | Cytokines | 6 | 2021 | 1824 | 0.340 |
Why?
| | Lung Diseases | 1 | 2015 | 690 | 0.310 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2021 | 144 | 0.300 |
Why?
| | Vitiligo | 2 | 2019 | 41 | 0.280 |
Why?
| | Mice | 16 | 2021 | 14841 | 0.260 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2020 | 580 | 0.250 |
Why?
| | Disease Models, Animal | 6 | 2016 | 3498 | 0.250 |
Why?
| | Animals | 20 | 2023 | 31565 | 0.250 |
Why?
| | Flow Cytometry | 6 | 2015 | 1075 | 0.250 |
Why?
| | Autoimmune Diseases | 2 | 2019 | 381 | 0.230 |
Why?
| | Herpesvirus 3, Human | 2 | 2019 | 377 | 0.230 |
Why?
| | Receptors, CCR5 | 2 | 2021 | 54 | 0.220 |
Why?
| | Herpesvirus 2, Human | 1 | 2023 | 27 | 0.220 |
Why?
| | Guinea Pigs | 1 | 2023 | 136 | 0.220 |
Why?
| | Viral Envelope Proteins | 1 | 2023 | 73 | 0.210 |
Why?
| | Lymphocyte Activation | 2 | 2018 | 1036 | 0.210 |
Why?
| | Interleukin-1 | 2 | 2019 | 965 | 0.210 |
Why?
| | Antibodies, Viral | 2 | 2023 | 520 | 0.200 |
Why?
| | Smokers | 2 | 2020 | 129 | 0.200 |
Why?
| | Humans | 32 | 2022 | 114043 | 0.200 |
Why?
| | Immunity, Innate | 2 | 2019 | 720 | 0.190 |
Why?
| | Firmicutes | 1 | 2021 | 17 | 0.180 |
Why?
| | Up-Regulation | 3 | 2019 | 802 | 0.180 |
Why?
| | Melanoma, Experimental | 1 | 2021 | 89 | 0.180 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2021 | 56 | 0.170 |
Why?
| | Female | 14 | 2023 | 59325 | 0.170 |
Why?
| | T-Lymphocytopenia, Idiopathic CD4-Positive | 1 | 2020 | 7 | 0.170 |
Why?
| | Haplotypes | 2 | 2019 | 448 | 0.170 |
Why?
| | Immunophenotyping | 1 | 2020 | 274 | 0.170 |
Why?
| | Homeodomain Proteins | 3 | 2012 | 463 | 0.160 |
Why?
| | Lung | 4 | 2022 | 3521 | 0.160 |
Why?
| | Germ-Free Life | 1 | 2019 | 28 | 0.160 |
Why?
| | RNA, Ribosomal, 16S | 2 | 2019 | 485 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2022 | 1128 | 0.160 |
Why?
| | Hexosaminidases | 1 | 2019 | 17 | 0.160 |
Why?
| | HLA-DQ Antigens | 2 | 2019 | 174 | 0.160 |
Why?
| | Dysbiosis | 2 | 2021 | 145 | 0.160 |
Why?
| | Genes, MHC Class II | 1 | 2019 | 69 | 0.160 |
Why?
| | Disease | 1 | 2019 | 85 | 0.160 |
Why?
| | Mice, Transgenic | 3 | 2019 | 1947 | 0.150 |
Why?
| | Immune System | 1 | 2019 | 171 | 0.150 |
Why?
| | Colony Count, Microbial | 1 | 2018 | 111 | 0.150 |
Why?
| | Neoplasm Proteins | 1 | 2021 | 385 | 0.150 |
Why?
| | HIV | 1 | 2019 | 208 | 0.150 |
Why?
| | Principal Component Analysis | 1 | 2018 | 177 | 0.140 |
Why?
| | Nitriles | 1 | 2018 | 149 | 0.140 |
Why?
| | Toll-Like Receptors | 1 | 2018 | 167 | 0.140 |
Why?
| | HIV-2 | 1 | 2016 | 15 | 0.140 |
Why?
| | Dideoxynucleosides | 1 | 2016 | 20 | 0.140 |
Why?
| | Heterocyclic Compounds, 3-Ring | 1 | 2016 | 28 | 0.140 |
Why?
| | Lamivudine | 1 | 2016 | 59 | 0.130 |
Why?
| | Inflammasomes | 1 | 2018 | 115 | 0.130 |
Why?
| | Intestinal Mucosa | 1 | 2021 | 532 | 0.130 |
Why?
| | Immune Evasion | 1 | 2015 | 47 | 0.120 |
Why?
| | Software | 1 | 2019 | 527 | 0.120 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2016 | 170 | 0.120 |
Why?
| | Cord Blood Stem Cell Transplantation | 1 | 2016 | 91 | 0.120 |
Why?
| | Retroviridae Infections | 1 | 2015 | 46 | 0.120 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2015 | 188 | 0.120 |
Why?
| | HIV Antigens | 1 | 2015 | 17 | 0.120 |
Why?
| | Inflammation Mediators | 1 | 2018 | 475 | 0.120 |
Why?
| | HLA-DR Antigens | 1 | 2016 | 219 | 0.120 |
Why?
| | Interleukin Receptor Common gamma Subunit | 2 | 2011 | 14 | 0.120 |
Why?
| | Male | 11 | 2022 | 55396 | 0.120 |
Why?
| | Gels | 2 | 2012 | 72 | 0.120 |
Why?
| | Chemistry, Pharmaceutical | 2 | 2012 | 98 | 0.120 |
Why?
| | Down-Regulation | 2 | 2016 | 594 | 0.120 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2016 | 256 | 0.110 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2016 | 350 | 0.110 |
Why?
| | CD4 Lymphocyte Count | 2 | 2012 | 256 | 0.110 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 396 | 0.110 |
Why?
| | Colitis | 1 | 2016 | 223 | 0.110 |
Why?
| | Receptors, Interleukin-1 | 1 | 2015 | 228 | 0.110 |
Why?
| | Macrophages | 2 | 2018 | 1259 | 0.110 |
Why?
| | Smoking | 1 | 2020 | 1382 | 0.110 |
Why?
| | HIV Envelope Protein gp120 | 2 | 2012 | 56 | 0.100 |
Why?
| | DNA-Binding Proteins | 4 | 2012 | 1311 | 0.100 |
Why?
| | Middle Aged | 7 | 2020 | 26605 | 0.100 |
Why?
| | HIV Antibodies | 1 | 2012 | 49 | 0.100 |
Why?
| | T-Lymphocytes | 2 | 2018 | 1735 | 0.100 |
Why?
| | Gastrointestinal Tract | 1 | 2014 | 169 | 0.100 |
Why?
| | Interleukin-1beta | 3 | 2021 | 368 | 0.100 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2019 | 907 | 0.090 |
Why?
| | Adult | 7 | 2020 | 30375 | 0.090 |
Why?
| | Raltegravir Potassium | 1 | 2010 | 16 | 0.090 |
Why?
| | Placebos | 1 | 2011 | 197 | 0.090 |
Why?
| | Mice, Inbred BALB C | 4 | 2016 | 1144 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 1 | 2019 | 2090 | 0.090 |
Why?
| | Antibodies, Neutralizing | 1 | 2012 | 222 | 0.090 |
Why?
| | Hematopoiesis | 1 | 2011 | 170 | 0.090 |
Why?
| | Lipopolysaccharides | 3 | 2019 | 813 | 0.080 |
Why?
| | Cell Lineage | 1 | 2011 | 308 | 0.080 |
Why?
| | Biomarkers | 2 | 2019 | 3397 | 0.080 |
Why?
| | Mice, Knockout | 4 | 2021 | 2562 | 0.080 |
Why?
| | Administration, Oral | 1 | 2010 | 725 | 0.080 |
Why?
| | RNA, Viral | 2 | 2011 | 565 | 0.080 |
Why?
| | Models, Genetic | 1 | 2011 | 559 | 0.070 |
Why?
| | Sindbis Virus | 1 | 2007 | 9 | 0.070 |
Why?
| | Hematopoietic Stem Cells | 1 | 2011 | 338 | 0.070 |
Why?
| | Case-Control Studies | 1 | 2015 | 3003 | 0.070 |
Why?
| | Nanoparticles | 1 | 2011 | 312 | 0.070 |
Why?
| | Nucleic Acid Conformation | 1 | 2011 | 670 | 0.070 |
Why?
| | 3' Untranslated Regions | 1 | 2007 | 129 | 0.070 |
Why?
| | Antigens, CD | 2 | 2020 | 440 | 0.070 |
Why?
| | Young Adult | 5 | 2020 | 10444 | 0.070 |
Why?
| | Antibodies, Monoclonal | 1 | 2012 | 1257 | 0.060 |
Why?
| | Sexual Behavior | 2 | 2020 | 434 | 0.060 |
Why?
| | Antiviral Agents | 1 | 2011 | 642 | 0.060 |
Why?
| | Interleukin-6 | 2 | 2022 | 673 | 0.060 |
Why?
| | Gene Expression Regulation | 3 | 2019 | 2321 | 0.060 |
Why?
| | Mice, Inbred C57BL | 3 | 2019 | 4680 | 0.060 |
Why?
| | Cohort Studies | 3 | 2019 | 4883 | 0.060 |
Why?
| | Cells, Cultured | 3 | 2018 | 3861 | 0.050 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2022 | 29 | 0.050 |
Why?
| | Bacteroides fragilis | 1 | 2022 | 11 | 0.050 |
Why?
| | Interleukin-12 | 1 | 2022 | 110 | 0.050 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2022 | 140 | 0.050 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2022 | 147 | 0.050 |
Why?
| | Immunologic Factors | 1 | 2022 | 217 | 0.040 |
Why?
| | Ribonuclease III | 2 | 2011 | 34 | 0.040 |
Why?
| | Integrin alpha Chains | 1 | 2020 | 22 | 0.040 |
Why?
| | Genome, Bacterial | 1 | 2021 | 106 | 0.040 |
Why?
| | Host-Pathogen Interactions | 2 | 2016 | 295 | 0.040 |
Why?
| | RNA, Messenger | 2 | 2019 | 2550 | 0.040 |
Why?
| | Bacteroides | 1 | 2019 | 16 | 0.040 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 1 | 2019 | 14 | 0.040 |
Why?
| | Hepatitis A Virus Cellular Receptor 2 | 1 | 2019 | 26 | 0.040 |
Why?
| | Spondylarthritis | 1 | 2019 | 36 | 0.040 |
Why?
| | HLA-DQ beta-Chains | 1 | 2019 | 57 | 0.040 |
Why?
| | CTLA-4 Antigen | 1 | 2019 | 76 | 0.040 |
Why?
| | Macrophages, Peritoneal | 1 | 2019 | 93 | 0.040 |
Why?
| | Coculture Techniques | 1 | 2019 | 198 | 0.040 |
Why?
| | Colon | 1 | 2020 | 232 | 0.040 |
Why?
| | DNA, Bacterial | 1 | 2019 | 312 | 0.040 |
Why?
| | Genetic Loci | 1 | 2019 | 262 | 0.040 |
Why?
| | Protein Transport | 1 | 2019 | 391 | 0.040 |
Why?
| | Caspase 1 | 1 | 2018 | 140 | 0.040 |
Why?
| | In Vitro Techniques | 1 | 2019 | 1003 | 0.040 |
Why?
| | Base Sequence | 2 | 2012 | 2114 | 0.030 |
Why?
| | Adolescent | 3 | 2020 | 17800 | 0.030 |
Why?
| | Oxazines | 1 | 2016 | 25 | 0.030 |
Why?
| | Virus Diseases | 1 | 2019 | 195 | 0.030 |
Why?
| | Interleukin-18 | 1 | 2018 | 217 | 0.030 |
Why?
| | Adventitia | 1 | 2016 | 37 | 0.030 |
Why?
| | Biopsy | 1 | 2020 | 1024 | 0.030 |
Why?
| | Aged | 3 | 2019 | 18969 | 0.030 |
Why?
| | Cell Nucleus | 1 | 2019 | 552 | 0.030 |
Why?
| | Monocytes | 1 | 2019 | 503 | 0.030 |
Why?
| | Neuroglia | 1 | 2016 | 149 | 0.030 |
Why?
| | Dendritic Cells | 1 | 2019 | 435 | 0.030 |
Why?
| | Pyridones | 1 | 2016 | 122 | 0.030 |
Why?
| | Retroviridae | 1 | 2015 | 89 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2019 | 284 | 0.030 |
Why?
| | Herpesviridae Infections | 1 | 2016 | 138 | 0.030 |
Why?
| | NF-kappa B | 1 | 2019 | 636 | 0.030 |
Why?
| | Immobilized Proteins | 1 | 2015 | 11 | 0.030 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 377 | 0.030 |
Why?
| | Neutralization Tests | 1 | 2015 | 63 | 0.030 |
Why?
| | Herpes Zoster | 1 | 2019 | 330 | 0.030 |
Why?
| | Enhancer Elements, Genetic | 1 | 2016 | 151 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 314 | 0.030 |
Why?
| | Mortality | 1 | 2016 | 283 | 0.030 |
Why?
| | Extracellular Space | 1 | 2015 | 116 | 0.030 |
Why?
| | Piperazines | 1 | 2016 | 310 | 0.030 |
Why?
| | T-Lymphocyte Subsets | 1 | 2016 | 383 | 0.030 |
Why?
| | Endotoxemia | 1 | 2015 | 86 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2015 | 249 | 0.030 |
Why?
| | Genotype | 1 | 2019 | 1757 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 949 | 0.030 |
Why?
| | Survivors | 1 | 2016 | 412 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2015 | 771 | 0.030 |
Why?
| | Protein Structure, Tertiary | 1 | 2015 | 796 | 0.030 |
Why?
| | Lymphocyte Depletion | 1 | 2012 | 115 | 0.030 |
Why?
| | Anti-Retroviral Agents | 1 | 2014 | 207 | 0.020 |
Why?
| | Administration, Topical | 1 | 2012 | 137 | 0.020 |
Why?
| | Fibroblasts | 1 | 2016 | 834 | 0.020 |
Why?
| | rev Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 5 | 0.020 |
Why?
| | Dendrimers | 1 | 2011 | 13 | 0.020 |
Why?
| | tat Gene Products, Human Immunodeficiency Virus | 1 | 2011 | 20 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1228 | 0.020 |
Why?
| | Peritoneum | 1 | 2011 | 36 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2011 | 75 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2011 | 88 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 2784 | 0.020 |
Why?
| | DEAD-box RNA Helicases | 1 | 2011 | 56 | 0.020 |
Why?
| | Lymphoid Tissue | 1 | 2011 | 62 | 0.020 |
Why?
| | Immunoglobulins | 1 | 2011 | 143 | 0.020 |
Why?
| | Viremia | 1 | 2011 | 122 | 0.020 |
Why?
| | Mucous Membrane | 1 | 2011 | 108 | 0.020 |
Why?
| | Antibody Formation | 1 | 2011 | 266 | 0.020 |
Why?
| | Disease Susceptibility | 1 | 2011 | 316 | 0.020 |
Why?
| | HIV Envelope Protein gp160 | 1 | 2009 | 7 | 0.020 |
Why?
| | SELEX Aptamer Technique | 1 | 2009 | 14 | 0.020 |
Why?
| | Prognosis | 1 | 2016 | 3315 | 0.020 |
Why?
| | Mutation | 1 | 2019 | 3338 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 1880 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2019 | 5038 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 4501 | 0.020 |
Why?
| | Interferon Type I | 1 | 2009 | 128 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2019 | 6306 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2015 | 1695 | 0.020 |
Why?
| | Cricetinae | 1 | 2007 | 252 | 0.020 |
Why?
| | Molecular Weight | 1 | 2007 | 328 | 0.020 |
Why?
| | Sequence Deletion | 1 | 2007 | 166 | 0.020 |
Why?
| | Aedes | 1 | 2007 | 55 | 0.020 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1624 | 0.020 |
Why?
| | RNA Stability | 1 | 2007 | 90 | 0.020 |
Why?
| | Risk Factors | 1 | 2020 | 8614 | 0.020 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2011 | 519 | 0.020 |
Why?
| | Infant | 1 | 2019 | 7943 | 0.020 |
Why?
| | Child, Preschool | 1 | 2019 | 9114 | 0.020 |
Why?
| | Brain | 1 | 2016 | 2355 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2009 | 2783 | 0.010 |
Why?
| | Liver | 1 | 2011 | 1633 | 0.010 |
Why?
| | Cell Line | 1 | 2007 | 2629 | 0.010 |
Why?
| | Proteins | 1 | 2007 | 906 | 0.010 |
Why?
| | Child | 1 | 2019 | 18400 | 0.010 |
Why?
|
|
Neff's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|